H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $21 from $22 and keeps a Buy rating on the shares following the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Increased Losses Amidst Ongoing Development
- Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year
- Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences price target raised to $22 from $15 at Citi